# A Global Multi-center Clinical Study of SARS-CoV-2 mRNA Vaccine for the Prevention of COVID-19

> **NCT05682638** · PHASE3 · UNKNOWN · sponsor: **AIM Vaccine Co., Ltd.** · enrollment: 34000 (estimated)

## Conditions studied

- SARS-CoV-2

## Interventions

- **BIOLOGICAL:** LVRNA009
- **OTHER:** 0.9%NaCl

## Key facts

- **NCT ID:** NCT05682638
- **Lead sponsor:** AIM Vaccine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-01-30
- **Primary completion:** 2024-12
- **Final completion:** 2025-12
- **Target enrollment:** 34000 (ESTIMATED)
- **Last updated:** 2023-02-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05682638

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05682638, "A Global Multi-center Clinical Study of SARS-CoV-2 mRNA Vaccine for the Prevention of COVID-19". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05682638. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*